Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

NCT03720496 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-hodgkin Lymphoma,B Cell

Interventions

BIOLOGICAL: CD19-TriCAR-T

Sponsor

Timmune Biotech Inc.